Breaks Categories: Analyst Alerts

WednesdayApr 28, 2021 10:16 am

NetworkNewsBreaks – Axsome Therapeutics, Inc. (NASDAQ: AXSM) Featured in Mizuho Securities Research Report

Axsome Therapeutics (NASDAQ: AXSM) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “AXS-05 Accepted and Granted Priority Review for Major Depressive Disorder: Axsome announced today that the FDA has accepted the company's New Drug Application (‘NDA’) for AXS-05 for the major depressive disorder (‘MDD’) indication. Importantly, the FDA has also granted the application Priority Review status, which shortens the review time from ten months to six months and sets up a Prescription Drug User Fee Act (‘PDUFA’) target action date of August 22, 2021. The news is in-line with our expectations,…

Continue Reading

FridayApr 23, 2021 3:06 pm

NetworkNewsBreaks – Coherus BioSciences, Inc. (NASDAQ: CHRS) Featured in Mizuho Securities Research Report

Coherus BioSciences (NASDAQ: CHRS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, Coherus announced that toripalimab (tori) in combination with chemo significantly prolonged PFS and OS in patients with advanced esophageal squamous cell carcinoma (‘ESCC’), compared w/ chemo alone. Despite the press release not containing numbers, we had a look at the benchmark data for anti-PD1s in combo w/ chemo being studied in this indication, as well as its potential market size, to start to do work around it. Overall, an incremental win for Coherus as the Junshi thesis…

Continue Reading

ThursdayApr 22, 2021 2:12 pm

NetworkNewsBreaks – Biogen Inc. (NASDAQ: BIIB) Featured in Mizuho Securities Research Report

Biogen (NASDAQ: BIIB) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Housekeeping: (1) Revenues came in line, but would have slightly missed if you back out the $40MM benefit of inventory in Spinraza ROW, and (2) there was a slight bump to EPS guidance for the year on reduced R&D. Note, Rituxan and Tecfidera erosion is occurring faster than expected. . . . Aducanumab: Language largely unchanged -- still in the guide. The slides discuss 600 clinical sites in the US that will be able to treat "shortly after potential approval".…

Continue Reading

ThursdayApr 15, 2021 11:16 am

NetworkNewsBreaks – BridgeBio Pharma, Inc. (NASDAQ: BBIO) Featured in Mizuho Securities Research Report

BridgeBio Pharma, Inc. (NASDAQ: BBIO) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning BridgeBio announced seven collaborations with US and Canadian academic and research institutions to take its total up to 20. It caught my eye. . . . It's especially timely, as one of things that is currently bubbling up in my conversations with folks is this topic of portfolio-based biotechs. We're seeing more of this now more than ever. Obviously, there is BridgeBio. Centessa launched a month ago with a $250MM Series A. Marc Appel's Orange Grove…

Continue Reading

ThursdayApr 15, 2021 11:15 am

NetworkNewsBreaks – Cytokinetics, Inc. (NASDAQ: CYTK) Featured in Mizuho Securities Research Report

Cytokinetics, Inc. (NASDAQ: CYTK) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Well, we are now well into April (yay for spring!), and if you're not aware, April 2021 is the designated month listed in the primary completion field on clinicaltrials.gov for CYTK's CK-274 Ph2 REDWOOD-HCM trial. This is going to be an important readout for CYTK and data is expected "mid-2021," per CYTK (note: we think May, unless CYTK clarifies with more granularity). Recall, the elevator pitch for CYTK is MYOK's mavacamten was sold to BMY for ~$13Bn. CYTK's CK-274…

Continue Reading

FridayApr 09, 2021 10:47 am

NetworkNewsBreaks – Roblox Corporation (NYSE: RBLX) Featured in Analysis Report

Roblox (NYSE: RBLX), focused on bringing the world together through play, was featured in a recent LikeFolio analysis report that discussed its performance since its debut into public trading. The report, written by LikeFolio Founder Andy Swan, reads, “On Monday, several investment banks initiated buy ratings for the video game company Roblox (NYSE: RBLX). Although the stock has been trading publicly for less than a month, LikeFolio has maintained a bullish outlook from the onset of coverage. Purchase intent mentions for the gaming platform rose to a new ATH in 21Q1 (ended 3/31), up +79% from the prior year. Shares…

Continue Reading

FridayApr 09, 2021 10:42 am

NetworkNewsBreaks – Gap Inc. (NYSE: GPS) Featured in Analysis Report

Gap (NYSE: GPS), an American worldwide clothing and accessories retailer, was featured in a recent LikeFolio analysis report that discussed a hefty but limited increase in demand for leisurewear during the COVID lockdowns, and Gap’s Athleta brand’s continued strong performance. The report, written by LikeFolio Founder Andy Swan, reads, “Athleta purchase intent mentions rose +24% YoY in the 4th quarter of 2020 (ended 1/31/21), a 4th consecutive quarter with YoY growth. GPS reported that Athleta grew 16% in 2020, surpassing $1 billion in revenue for the year. A telling sign of Athleta’s current strength is its relative outperformance when compared…

Continue Reading

FridayApr 09, 2021 10:21 am

NetworkNewsBreaks – Tesla Inc. (NASDAQ: TSLA) Featured in Analysis Report

Tesla (NASDAQ: TSLA), an American electric vehicle (“EV”) and clean energy company, was featured in a recent analysis report titled, “Tesla Deliveries Crush Estimates,” that discussed its soaring performance. The report, written by LikeFolio Founder Andy Swan, reads, “Consumer purchase intent mentions for Tesla (NASDAQ: TSLA) soared to a new ATH in 21Q1, up +75% YoY. Last week, LikeFolio released a Bullish Opportunity Alert based on the strong uptrend in underlying consumer demand… And, we’ve already been vindicated. Tesla released its Q1 delivery report on Friday, which greatly surpassed market expectations. Shares are up +5.5% on the news.” About Tesla…

Continue Reading

TuesdayApr 06, 2021 9:47 am

NetworkNewsBreaks – ContraFect Corp. (NASDAQ: CFRX) Featured in Mizuho Securities Research Report

ContraFect Corp. (NASDAQ: CFRX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “ContraFect released 4Q20 earnings that were essentially a non-event, as is often the case for a clinical-stage company. The company's recent BARDA contract and equity raise solidifies its capital position and adds external credibility to the exebacase program. Attention now shifts back to the DISRUPT trial, with interim data expected in 2H 2021 and final data in 2022. We maintain our 70% POS for DISRUPT at the final analysis given the strength of the Phase 2 exebacase data in…

Continue Reading

MondayMar 29, 2021 3:23 pm

NetworkNewsBreaks – Uranium Energy Corp. (NYSE American: UEC) Receives ‘Buy’ Rating from H.C. Wainwright & Co.

Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company, recently announced the close an offering of 10 million shares, resulting in an estimated $30.5 million for the company. According to the announcement, the company plans to use the funds to support its physical uranium purchase initiative as well as for general corporate and working capital requirements. Based on the company’s announcement, H.C. Wainwright & Co. released a target price revision; the report noted a price of $2.65 and a buy rating. “While the company remains focused on developing its low-cost, in-situ recovery (‘ISR’) mining capabilities, management has…

Continue Reading